Journal Browser

► Journal Browser

Special Issue "Biological/Targeted Therapy of Immune-Mediated Skin Diseases 2.0"

Share This Special Issue

Special Issue Editors

Special Issue Information

Dear Colleagues,

You are kindly invited to submit your scientifically valuable contributions to this Special Issue of Vaccines.

Our goal is to collect a series of manuscripts that report on the biological/targeted therapy of immune-mediated skin diseases. Inflammatory and immune-mediated diseases are highly prevalent, and have great relevance to general medicine and dermatology. Pathways common to different diseases are being elucidated, and many new treatment options are becoming available, thus increasing the need for sharing basic, translational and clinical research findings. We hope to receive scientific contributions that provide new insights, particularly in terms of therapies for inflammatory and immune-mediated diseases such as psoriasis, atopic dermatitis, hidradenitis suppurativa, autoimmune bullous diseases, urticaria and itch.

Thank you for considering our invitation.

Prof. Dr. Paolo Gisondi
Dr. Francesco Bellinato
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

psoriasis
atopic dermatitis
vitiligo
alopecia areata
autoimmune bullous diseases
hidradenitis suppurativa
biologic therapy
vasculitis
urticaria
itch

Published Papers (2 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

Jump to: Review

Open AccessArticle

Characteristics of Patients Experiencing a Flare of Generalized Pustular Psoriasis: A Multicenter Observational Study

Francesco Bellinato

Paolo Gisondi

Angelo Valerio Marzano

and

Vaccines 2023, 11(4), 740; https://doi.org/10.3390/vaccines11040740 - 27 Mar 2023

Cited by 1 | Viewed by 1412

Abstract

Background: Generalized pustular psoriasis (GPP) is a rare, severe inflammatory skin disease characterized by recurrent episodes of flares. Characteristics of patients experiencing a flare are hardly described in a real-life setting. The aim of the study is to investigate the clinical characteristics of patients experiencing a flare of GPP. Methods: Multicenter retrospective observational study on consecutive patients experiencing a flare of GPP between 2018 and 2022. Disease severity and quality of life were assessed by Generalized Pustular Psoriasis Area, Body Surface Area (BSA), and Severity Index (GPPASI), and Dermatology life quality index (DLQI) questionnaire, respectively. Visual analogue scale (VAS) of itch and pain, triggers, complications, comorbidities, pharmacological therapies, and outcome were collected. Results: A total of 66 patients, 45 (68.2%) females, mean age 58.1 ± 14.9 years, were included. The GPPASI, BSA, and DLQI were 22.9 ± 13.5 (mean ± standard deviation), 47.9 ± 29.1, and 21.0 ± 5.0, respectively. The VAS of itch and pain were 6.2 ± 3.3 and 6.2 ± 3.0, respectively. Fever (>38 °C) and leukocytosis (WBC > 12 × 10⁹/L) were found in 26 (39.4%) and 39 (59.1%) patients, respectively. Precipitating triggers were identified in 24 (36.3%) and included infections (15.9%), drugs (10.6%), stressful life events (7.6%), and corticosteroids withdrawal (3.0%). Fourteen (21.2%) patients were hospitalized because of complications including infections in 9 (13.6%) leading to death in one case and hepatitis in 3 (4.5%). Conclusions: GPP flares can be severe and cause severe pain and itch with significant impact on the quality of life. In about one-third of patients the flare may have a persistent course and, with complications, lead to hospitalization. Full article

(This article belongs to the Special Issue Biological/Targeted Therapy of Immune-Mediated Skin Diseases 2.0)

Review

Jump to: Research

Open AccessReview

Cutaneous Adverse Reactions to SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis

and

Vaccines 2022, 10(9), 1475; https://doi.org/10.3390/vaccines10091475 - 06 Sep 2022

Cited by 8 | Viewed by 1487

Abstract

Background: An increasing number of cutaneous adverse reactions (CARs) to SARS-CoV-2 vaccines have been reported, but their incidence is debated. Objective: To estimate the pooled incidence of CARs to SARS-CoV-2 vaccines in the general adult population. Methods: A systematic review and meta-analysis of original articles published on MEDLINE via PubMed and Web Of Science from 1 January 2020 to 18 July 2022 was undertaken. Studies reporting the incidence proportion of CARs (defined as number of new cases of CARs on the total of vaccinated people) were included. All types of SARS-CoV-2 vaccine were included. People receiving at least one dose were considered eligible. Local cutaneous reactions were excluded. Results: A total of 970 records were identified and screened by title and abstract; 22 observational studies were included with aggregate data on 93,165 participants. The pooled incidence of overall CARs was 5% (95%CI 4–6%; I² = 99%; p < 0.001), ranging from <0.01 to 19.00%. Most CARs were new onset dermatitis including rash, urticaria and vascular lesions; one case of Steven–Johnson syndrome and six cases of erythema multiforme were reported. In the sensitivity analysis we found that the incidence of CARs after the first and second dose was similar, i.e., 3% (95%CI 2–3%; I² = 96%; p < 0.001) and 3% (95%CI 2–4%; I² = 97%; p < 0.001), respectively. The magnitude of incidence of CARs remained unchanged independently of vaccine platform and in the general population versus healthcare workers. Conclusions: CARs associated with SARS-CoV-2 vaccines are frequent but mild and self-remitting, whereas severe CARs are rare. Full article

(This article belongs to the Special Issue Biological/Targeted Therapy of Immune-Mediated Skin Diseases 2.0)

► Show Figures

Journal Menu

Journal Browser

Special Issue "Biological/Targeted Therapy of Immune-Mediated Skin Diseases 2.0"

Share This Special Issue

Special Issue Editors

Special Issue Information

Keywords

Published Papers (2 papers)

Research

Review

Further Information

Guidelines

MDPI Initiatives

Follow MDPI